{"id":"NCT01674647","sponsor":"Bayer","briefTitle":"Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion","officialTitle":"A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10","primaryCompletion":"2014-01","completion":"2014-01","firstPosted":"2012-08-29","resultsPosted":"2015-02-03","lastUpdate":"2015-04-30"},"enrollment":1504,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Atrial Fibrillation"],"interventions":[{"type":"DRUG","name":"Rivaroxaban (Xarelto, BAY59-7939)","otherNames":[]},{"type":"DRUG","name":"Vitamin K antagonist (VKA)","otherNames":[]}],"arms":[{"label":"Rivaroxaban (Xarelto, BAY59-7939)","type":"EXPERIMENTAL"},{"label":"Vitamin K antagonist (VKA)","type":"ACTIVE_COMPARATOR"}],"summary":"A study for patients with abnormal heart rhythm (atrial fibrillation) who need to undergo cardioversion (procedure to restore normal heart rhythm). The study will compare patients assigned randomly (like flipping a coin) to either Rivaroxaban or vitamin K antagonist (VKA). The study will measure common medical outcomes for this type of patient such as bleeding and stroke.","primaryOutcome":{"measure":"Number of Participants With Composite of the Following Events, Adjudicated Centrally: Stroke, Transient Ischemic Attack, Non-central Nervous System Systemic Embolism, Myocardial Infarction and Cardiovascular Death","timeFrame":"From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment","effectByArm":[{"arm":"Rivaroxaban (Xarelto, BAY59-7939)","deltaMin":5,"sd":null},{"arm":"Vitamin K Antagonist (VKA)","deltaMin":5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":10},"locations":{"siteCount":178,"countries":["United States","Belgium","Brazil","Canada","China","Denmark","Finland","France","Germany","Greece","Italy","Netherlands","Portugal","Singapore","South Africa","Spain","United Kingdom"]},"refs":{"pmids":["25182247","24944325"],"seeAlso":["http://www.clinicaltrialsregister.eu/"]},"adverseEventsSummary":{"seriousAny":{"events":93,"n":988},"commonTop":["Atrioventricular block first degree","Bradycardia","Epistaxis","Sinus bradycardia","Dizziness"]}}